90 related articles for article (PubMed ID: 18028241)
1. Long-term assessment of oxcarbazepine in a naturalistic setting: a retrospective study.
Seneviratne U; D'Souza W; Cook M
Acta Neurol Scand; 2008 May; 117(5):367-9. PubMed ID: 18028241
[TBL] [Abstract][Full Text] [Related]
2. Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics.
Rainesalo S; Peltola J; Auvinen A; Keränen T
Seizure; 2005 Jan; 14(1):72-4. PubMed ID: 15642505
[TBL] [Abstract][Full Text] [Related]
3. Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine.
Albani F; Baruzzi A;
Neurol Sci; 2006 Jul; 27(3):173-5. PubMed ID: 16897629
[TBL] [Abstract][Full Text] [Related]
4. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
[TBL] [Abstract][Full Text] [Related]
5. Three-Year Retention Rates of Levetiracetam, Topiramate, and Oxcarbazepine: A Retrospective Hospital-Based Study.
Sunwoo JS; Park BS; Ahn SJ; Hwang S; Park CY; Jun JS; Kim DW; Lee ST; Jung KH; Park KI; Chu K; Jung KY; Lee SK
Clin Neuropharmacol; 2017; 40(2):56-62. PubMed ID: 28118167
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy.
Dogan EA; Usta BE; Bilgen R; Senol Y; Aktekin B
Epilepsy Behav; 2008 Jul; 13(1):156-61. PubMed ID: 18331816
[TBL] [Abstract][Full Text] [Related]
7. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
8. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy.
Vendrame M; Khurana DS; Cruz M; Melvin J; Valencia I; Legido A; Kothare SV
Epilepsia; 2007 Nov; 48(11):2116-20. PubMed ID: 17645535
[TBL] [Abstract][Full Text] [Related]
9. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability.
Simister RJ; Sander JW; Koepp MJ
Epilepsy Behav; 2007 Mar; 10(2):336-9. PubMed ID: 17267290
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
Mintzer S; Boppana P; Toguri J; DeSantis A
Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614
[TBL] [Abstract][Full Text] [Related]
11. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy and tolerability of oxcarbazepine oral suspension between infants and children with epilepsy: a retrospective chart review at a single medical center in Taiwan.
Wei SH; Liu CC; Fan PC
Paediatr Drugs; 2014 Feb; 16(1):83-9. PubMed ID: 24081427
[TBL] [Abstract][Full Text] [Related]
14. A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis.
Lee WC; Hoffmann MS; Arcona S; D'Souza J; Wang Q; Pashos CL
Clin Ther; 2005 Oct; 27(10):1629-38. PubMed ID: 16330300
[TBL] [Abstract][Full Text] [Related]
15. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?
Schmidt D; Elger CE
Epilepsy Behav; 2004 Oct; 5(5):627-35. PubMed ID: 15380112
[TBL] [Abstract][Full Text] [Related]
16. Oxcarbazepine versus carbamazepine in the treatment of paroxysmal kinesigenic dyskinesia.
Yang Y; Su Y; Guo Y; Ding Y; Xu S; Jiang Y; Wang S; Ding M
Int J Neurosci; 2012 Dec; 122(12):719-22. PubMed ID: 22856516
[TBL] [Abstract][Full Text] [Related]
17. Oxcarbazepine therapy in very young children: a single-center clinical experience.
Kothare SV; Mostofi N; Khurana DS; Mohsem B; Melvin JJ; Hardison HH; Valencia I; Legido A
Pediatr Neurol; 2006 Sep; 35(3):173-6. PubMed ID: 16939855
[TBL] [Abstract][Full Text] [Related]
18. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.
Gelisse P; Genton P; Kuate C; Pesenti A; Baldy-Moulinier M; Crespel A
Epilepsia; 2004 Oct; 45(10):1282-6. PubMed ID: 15461683
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with oxcarbazepine in clinical practice.
Passarella B; Nozzoli C
Funct Neurol; 2005; 20(3):131-3. PubMed ID: 16324237
[TBL] [Abstract][Full Text] [Related]
20. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
Gaily E; Granström ML; Liukkonen E
J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():41-5. PubMed ID: 10030431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
